1. Home
  2. RNW vs VRDN Comparison

RNW vs VRDN Comparison

Compare RNW & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ReNew Energy Global plc

RNW

ReNew Energy Global plc

HOLD

Current Price

$6.18

Market Cap

2.2B

Sector

Utilities

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$23.36

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNW
VRDN
Founded
2011
2006
Country
United Kingdom
United States
Employees
4336
N/A
Industry
Electric Utilities: Central
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
RNW
VRDN
Price
$6.18
$23.36
Analyst Decision
Hold
Strong Buy
Analyst Count
1
14
Target Price
$7.00
$35.46
AVG Volume (30 Days)
1.2M
1.8M
Earning Date
06-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,706,000.00
Revenue This Year
N/A
$13.73
Revenue Next Year
$11.50
$279.00
P/E Ratio
$14.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.39
$13.18
52 Week High
$8.24
$34.29

Technical Indicators

Market Signals
Indicator
RNW
VRDN
Relative Strength Index (RSI) 52.42 72.21
Support Level $5.95 $22.14
Resistance Level $6.33 $34.18
Average True Range (ATR) 0.18 0.95
MACD 0.00 0.22
Stochastic Oscillator 67.86 99.77

Price Performance

Historical Comparison
RNW
VRDN

About RNW ReNew Energy Global plc

ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Share on Social Networks: